Bloedjes TA - Search Results

1

AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity.

Bloedjes TA, de Wilde G, Khan GH, Ashby TC, Shaughnessy JD, Zhan F, Houtkooper RH, Bende RJ, van Noesel CJM, Spaargaren M, Guikema JEJ. Bloedjes TA, et al. Blood Adv. 2023 May 9;7(9):1697-1712. doi: 10.1182/bloodadvances.2022007383. Blood Adv. 2023. PMID: 36322819 Free PMC article.

2

NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity.

Ochodnicka-Mackovicova K, Bahjat M, Bloedjes TA, Maas C, de Bruin AM, Bende RJ, van Noesel CJ, Guikema JE. Ochodnicka-Mackovicova K, et al. Among authors: bloedjes ta. Blood. 2015 Sep 10;126(11):1324-35. doi: 10.1182/blood-2015-01-621623. Epub 2015 Jul 7. Blood. 2015. PMID: 26153519 Free PMC article.

3

AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma.

Bloedjes TA, de Wilde G, Maas C, Eldering E, Bende RJ, van Noesel CJM, Pals ST, Spaargaren M, Guikema JEJ. Bloedjes TA, et al. Blood Adv. 2020 Sep 8;4(17):4151-4164. doi: 10.1182/bloodadvances.2019001393. Blood Adv. 2020. PMID: 32898245 Free PMC article.

4

Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma.

Bloedjes TA, de Wilde G, Guikema JEJ. Bloedjes TA, et al. Cancers (Basel). 2021 Jan 21;13(3):396. doi: 10.3390/cancers13030396. Cancers (Basel). 2021. PMID: 33494394 Free PMC article. Review.

5

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.

Bahjat M, de Wilde G, van Dam T, Maas C, Bloedjes T, Bende RJ, van Noesel CJM, Luijks DM, Eldering E, Kersten MJ, Guikema JEJ. Bahjat M, et al. Cell Cycle. 2019 Sep;18(18):2307-2322. doi: 10.1080/15384101.2019.1646068. Epub 2019 Jul 26. Cell Cycle. 2019. PMID: 31349760 Free PMC article.

6

The DNA Damage Response Regulates RAG1/2 Expression in Pre-B Cells through ATM-FOXO1 Signaling.

Ochodnicka-Mackovicova K, Bahjat M, Maas C, van der Veen A, Bloedjes TA, de Bruin AM, van Andel H, Schrader CE, Hendriks RW, Verhoeyen E, Bende RJ, van Noesel CJ, Guikema JE. Ochodnicka-Mackovicova K, et al. Among authors: bloedjes ta. J Immunol. 2016 Oct 1;197(7):2918-29. doi: 10.4049/jimmunol.1501989. Epub 2016 Aug 24. J Immunol. 2016. PMID: 27559048

7

Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay.

Bahjat M, Bloedjes TA, van der Veen A, de Wilde G, Maas C, Guikema JEJ. Bahjat M, et al. Among authors: bloedjes ta. J Vis Exp. 2017 Jun 9;(124):55703. doi: 10.3791/55703. J Vis Exp. 2017. PMID: 28654064 Free PMC article.

8

SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma.

Leeksma AC, Derks IAM, Garrick B, Jongejan A, Colombo M, Bloedjes T, Trowe T, Leisten JC, Howarth M, Malek M, Mortensen DS, Blease K, Groza MC, Narla RK, Loos R, Kersten MJ, Moerland PD, Guikema JEJ, Kater AP, Eldering E, Filvaroff EH. Leeksma AC, et al. Mol Oncol. 2023 Feb;17(2):284-297. doi: 10.1002/1878-0261.13343. Epub 2022 Dec 16. Mol Oncol. 2023. PMID: 36400430 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page